






































The Impact of KRASMutation in Patients With Sporadic
Nonampullary Duodenal Epithelial Tumors
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INTRODUCTION: The genomic characterization of primary nonampullary duodenal adenocarcinoma indicates a genetic
resemblance to gastric and colorectal cancers. However, a correlation between the clinical and
molecular characteristics of these cancers has not been established. This study aimed to elucidate the
clinicopathological features of sporadic nonampullary duodenal epithelial tumors, including their
molecular characteristics and prognostic factors.
METHODS: One hundred forty-eight patients with sporadic nonampullary duodenal epithelial tumors were
examined in this study. Patient sex, age, TNM stage, tumor location, treatment methods, histology,
KRAS mutation, BRAF mutation, Fusobacterium nucleatum, mucin phenotype, and programmed
death-ligand 1 (PD-L1) status were evaluated.KRAS andBRAFmutations, Fusobacterium nucleatum,
mucin phenotype, and PD-L1 status were analyzed by direct sequencing, quantitative polymerase
chain reaction, and immunochemical staining.
RESULTS: The median follow-up duration was 119.4 months. There were no deaths from duodenal adenoma (the
primary disease). Kaplan-Meier analysis for duodenal adenocarcinoma showed a significant effect of
TNM stage (P < 0.01). In univariate analysis of primary deaths from duodenal adenocarcinoma, TNM
stage II or higher, undifferentiated,KRASmutations, gastric phenotype, intestinal phenotype, and PD-
L1 status were significant factors. Inmultivariate analysis, TNM stage II or higher (hazard ratio: 1.633
1010, 95% confidence interval: 18.66–6.69 3 1036) and KRAS mutation (hazard ratio: 3.49,
confidence interval: 1.52–7.91) were significant factors.
DISCUSSION: Only KRAS mutation was a significant prognostic factor in primary sporadic nonampullary duodenal
adenocarcinoma in cases in which TNM stage was considered.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A717 and http://links.lww.com/CTG/A718
Clinical and Translational Gastroenterology 2021;12:e00424. https://doi.org/10.14309/ctg.0000000000000424
INTRODUCTION
In recent years, the clarification of gastrointestinal tumor char-
acteristics has been enabled by instrumentation and reagent de-
velopments in endoscopy andDNA sequencing (1). In particular,
the molecular biological characteristics of colorectal cancer have
been determined, and the choice of treatment such as EGFR in-
hibitors, BRAF inhibitors, angiogenesis inhibitors, and immune
checkpoint inhibitors differs in clinical practice depending on the
presence or absence of KRAS mutation, BRAF mutation, and
microsatellite instability (2). Tumor characteristics also contrib-
ute to prognosis, with anatomical location, such as the right or left
side of the colon, identified as an important factor in determining
treatment selection (3).
Sporadic nonampullary duodenal epithelial tumors (SNA-
DETs) have been reported periodically. However, low detection
rates compared with gastric and colorectal tumors have ham-
pered efforts to analyze their clinicopathology. The prevalence of
SNADETs is extremely low (0.02%–0.5%) (4–6), and primary
sporadic nonampullary duodenal adenocarcinoma accounts for
only 0.5% of all gastrointestinal malignancies (7). However,
SNADET detection rates have improved with the development of
endoscopic diagnosis techniques (8). Furthermore, SNADETs
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cases with a poor prognosis are on the rise (9). Consequently, the
importance of research into SNADETs clinicopathology has been
recognized, and their characteristics are becoming clearer as a
result (10–12).
Whole-genome sequencing has revealed new insights into the
genes involved in primary sporadic nonampullary duodenal ad-
enocarcinoma (13). The genomic characterization of primary
sporadic nonampullary duodenal adenocarcinoma indicates a
genetic resemblance to gastric and colorectal cancers (13).
However, a correlation between the clinical and molecular
characteristics of these cancers has not been elucidated. On the
other hand, the anatomical location of the tumor on the oral side
of the papilla of Vater (oral side of Vater) (14,15), gastric mucin
phenotype, which is one of the mucin phenotypes of the tumor
(15,16), and programmed death-ligand 1 (PD-L1) status (17) are
currently being investigated as factors potentially contributing to
the prognosis of SNADETs. However, because of its rarity, the
role of these factors has not been revealed in specific types of
SNADETs, including duodenal adenoma and early- to advanced-
stage duodenal adenocarcinoma.
In this study, prognostic factors were investigated in 148 pa-
tients with SNADETs. The analysis focused not only on tumor
location, mucin phenotype, and PD-L1 status but also on factors
such as KRAS and BRAF mutations, which are important in co-
lorectal cancer. Furthermore, Fusobacterium nucleatum (Fn)
(18), which has attracted research attention regarding its role in




One hundred forty-eight patients with SNADETs, treated at the
Okayama University Hospital and Hiroshima City Hospital in
Japan from 2006 to 2018, were enrolled in this study. Tissue
samples were collected in all cases. Demographic, clinicopatho-
logical, and tumor characteristics were investigated and included
patient sex, age, TNM stage, tumor location, treatment methods,
histology, KRAS mutation, BRAF mutation, Fn, mucin pheno-
type, and PD-L1 status. The SNADETswere staged in accordance
with the Union for International Cancer Control TNM staging
system (19). In this study, stages 0 and Ⅰwere defined as early stage
and stages II, III, and IV as advanced stage. Themedian follow-up
duration was 47.7 months (range, 0.2–163 months). Somatic
mutations of KRAS and BRAF, Fn, mucin phenotype, and PD-L1
status were examined by direct sequencing, real-time quantitative
polymerase chain reaction (qPCR), and immunohistochemistry.
Endoscopic treatment was used for adenomas and duodenal
adenocarcinoma (stage 0), surgery for duodenal cancer without
distant metastasis (stage II and stage III), and chemotherapy for
duodenal adenocarcinoma with distant metastasis (stage IV).
The Institutional Review Boards of Okayama University
Hospital andHiroshimaCityHospital approved this study (2103-
051/2021-8), which was conducted in accordance with the Dec-
laration of Helsinki. Patients provided either written informed
consent to participate or were required to opt out if their data
were accessed retrospectively.
DNA extraction
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were
obtained from patients who had been biopsied, or resected by
endoscopy or surgery, for SNADETs. All tissue sections were
reviewed by expert gastrointestinal pathologists (T.T. and K.I.).
Histological examinations confirmed that the samples contained
a minimum of 30% tumor cells. DNAwas extracted from five 10-
mm-thick sections of the FFPE samples using a QIAamp DNA
FFPE Tissue Kit (Qiagen, Valencia, CA), according to the man-
ufacturer’s instructions. AllDNAswere eluted in afinal volumeof
50 mL and stored at 230 C. DNAs extracted from FFPE were
quantified using a Qubit fluorometer (Thermo Fisher Scientific,
Waltham, MA).
Direct sequencing analysis
KRAS and BRAFwere amplified using polymerase chain reaction
(PCR) with forward and reverse primers (see Supplemental Ta-
ble 1, Supplementary Digital Content 1, http://links.lww.com/
CTG/A718). Each 50mL PCR reaction contained 100 nM of each
primer, 1 ng template DNA, and master mix reagent (AmpliTaq
Gold 360 PCRMasterMix; Applied Biosystems, Foster City, CA).
Amplification conditions consisted of 10 minutes at 94 C, fol-
lowed by 40 cycles at 94 C for 10 seconds, 55 C for 30 seconds,
and 72 C for 30 seconds, in a thermal cycler (GeneAmp PCR
System 9700; Applied Biosystems). The PCR products were
separated by electrophoresis on 2% agarose gels, stained with
ethidium bromide, and visualized under ultraviolet light. Then,
the PCR products were purified before direct sequencing was
performed using the Big Dye Terminator Cycle Sequencing kit
(Applied Biosystems) on an ABI Prism 310 genetic analyzer
(Applied Biosystems). KRASmutations in codons 12 and 13 and
BRAFmutation in codon 600were examined according to the raw
nucleotide sequencing data in waveform obtained by direct
sequencing.
Fn analysis
The amount of Fn DNA in tissues was measured by qPCR.
Custom-made primer/probe sets were used to amplify Fn and
the reference human gene solute carrier organic anion trans-
porter family number 2A1 (SLCO2A1), as previously described
(20). The primer and probe sequences are summarized in
Supplemental Table 1 (Supplementary Digital Content 1, http://
links.lww.com/CTG/A718). The qPCR was performed in 20 mL
reactions containing 30 ng of genomic DNA (2 mL), 13 final
concentration Prime time gene expressionMasterMix 2.0 (IDT,
Coralville, IA) (10 mL), each Prime qPCR assay (FAM/HEX) (1
mL), and deionized distilled water (6 mL). The DNA was am-
plified and detected with a Roche LightCycler 96 system (Roche,
Basel, Switzerland) under the following conditions: 10 minutes
at 95 C, then 45 cycles of 15 seconds at 95 C and 60 seconds
at 60 C.
All specimens were analyzed in duplicate. To exclude non-
specific PCR amplification, we regarded a specimen as Fn positive
when both specimens were positive. The amount of Fn DNA in
each tissue was calculated by 22DCt, where DCt was the differ-
ence in the Ct value of Fn and SLCO2A1. The mean of the 2 Ct
values for each reaction was used for analysis.
Histopathological examinations and Vienna classification
For histological analysis, SNADETs tissue specimens were rou-
tinely fixed with formalin and completely embedded in paraffin.
Tissue blocks were thinly sectioned, routinely processed, and
stained with hematoxylin and eosin. All SNADETs were histo-
logically graded based on the revised Vienna classification (VCL)
system (21). We defined VCL category 3 as low-grade adenoma/









dysplasia, 4.1 as high-grade adenoma/dysplasia, and 4.2 as car-
cinoma in situ. VCL categories 5.1 and 5.2 were considered as
intramucosal carcinoma and submucosal carcinoma or beyond,
respectively. We classified VCL categories 3 and 4.1 as adenoma
and 4.2 or more as adenocarcinoma. Adenocarcinoma was sub-
divided into differentiated or undifferentiated types depending on
histopathological grading. Two investigators (T.T. and K.I.)
assessed histological grade independently, and any disagreements
were resolved through consensus.
Immunohistochemical examinations
FFPE tissue blocks were cut into 3-mm-thick tissue sections and
subjected to hematoxylin and eosin and immunohistochemical
staining. Immunohistochemical staining was performed by the
standard avidin-biotin-peroxidase complex method with an
automated immunostainer (BenchMark XT; Ventana Medical
System, Tucson, AZ). Mucin phenotype of SNADETs was ex-
amined using MUC2 (Ccp58, monoclonal mouse; Dako, Den-
mark, UK), MUC5AC (CLH2, monoclonal mouse; Dako),
MUC6 (CLH5,monoclonalmouse; Novus Biologicals, Littleton,
CO), and CD10 (56C6, monoclonal mouse; Leica Biosystems,
Newcastle, UK). The tumor’s cytoplasmic immunoreactivity
was judged positive for MUC2, MUC5AC, andMUC6. Luminal
membranous immunoreactivity was judged positive for CD10.
Immunohistochemical staining for gastric phenotype markers
(MUC5AC and MUC6) and intestinal phenotype markers
(MUC2 and CD10) were considered positive when distinct
staining was observed in .10% of the cancer cells. The SNA-
DETs were classified into 4 subtypes based on mucin immu-
nohistochemistry: (1) gastric phenotype, (2) intestinal
phenotype, (3) gastric and intestinal phenotype (mixed phe-
notype), and (4) not staining (null phenotype) (see Supple-
mental Figure 1, Supplementary Digital Content 1, http://links.
lww.com/CTG/A717).
For PD-L1 staining, sections were retrieved in EDTA buffer
(pH8.0) at 98 C for 20minutes. Amonoclonal antibodywas used
against the membranous and cytoplasmic domain of PD-L1
(SP263, monoclonal rabbit; Ventana Medical Systems) in
immunostaining, and reactivity was evaluated for cancer cells.
PD-L1 positivity was defined as a positive cell staining of any
intensity on$1% of the cell membrane and cytoplasm.
Two investigators (T.T. and K.I.), blinded to the patients’
clinical information, collaboratively assessed the immunohisto-
chemical results as well as the histological analysis and VCL
classification.
Statistical analysis
All continuous variables are reported as the median (range), and
comparisons were made using the Wilcoxon rank-sum test. All
categorical variables are summarized as frequencies (percent-
ages), with Pearson x2 or Fisher exact tests used for examining
comparisons. Overall survival (OS) was estimated by the Kaplan-
Meier method, and differences were evaluated using the log-rank
test. A Cox proportional hazard model was used to assess OS by
TNM stage, tumor location, treatment methods,KRASmutation,
BRAF mutation, Fn, mucin phenotype, and PD-L1 status. All
statistical tests were 2 sided, and a P value less than 0.05 was
considered statistically significant. Statistical analyses were per-




Of the 148 patients with SNADETs, 55 and 93 had duodenal
adenomas and duodenal adenocarcinomas, respectively. The
median age was 67 years, and there were 97 men and 51 women.
Tumors were located on the oral (n5 79) or anal (n5 69) side of
the papilla of Vater. Some patients also received endoscopic
treatment (n5 71), surgical procedures (n5 59), chemotherapy
(n 5 9), and other treatments (n 5 9; Table 1).
There were no cases of primary mortality from duodenal ade-
noma. On the other hand, primary mortality from duodenal ade-
nocarcinoma increased with TNM stage, involving 0, 0, 4, 11, and
16 patient deaths from stages 0, I, II, III, and IV, respectively.
Kaplan-Meier analysis divided onTNMstage revealed a significant
effect on OS, as median survival was 93.1 months in stage II, 42.9
months in stage III, and 9.5months in stage IV (P, 0.01; Figure 1).
Genetic and epigenetic characteristics
Of the 148 patients with SNADETs, 33 had KRAS mutation, 13
had BRAF mutation, and 29 were Fn positive. Furthermore, a
range of patients demonstrated gastric phenotype (n 5 41), in-
testinal phenotype (n5 74), mixed phenotype (n5 24), and null
phenotype (n 5 9; Table 1).
Comparing the 55 patients with duodenal adenoma with the
93 patients with duodenal adenocarcinoma showed significant
differences in anatomical location (P, 0.01), treatment methods
(P, 0.01), BRAFmutation (P5 0.01), Fn (P5 0.03), and mucin
phenotype (P , 0.01). On the other hand, the 45 patients with
early-stage duodenal adenocarcinoma showed significant differ-
ences in anatomical location (P5 0.04), treatment methods (P,
0.01), tumor histology (P , 0.01), BRAF mutation (P 5 0.01),
mucin phenotype (P , 0.01), and PD-L1 status (P , 0.01)
compared with the 48 patients with advanced-stage duodenal
adenocarcinoma (Table 1).
Duodenal adenocarcinoma
Kaplan-Meier analysis of survival in duodenal adenocarcinoma
showed that TNM stage II or higher (P , 0.01), anatomical lo-
cation (oral side of Vater; P5 0.03), undifferentiated (P, 0.01),
KRAS mutation (P , 0.01), gastric phenotype (P 5 0.01), in-
testinal phenotype (P , 0.01), and PD-L1 status (P , 0.01) sig-
nificantly influenced patient outcomes (Figures 1–3).
In univariate analysis of primary mortality from duodenal
adenocarcinoma, TNM stage II or higher (hazard ratio [HR]: 1.8
3 1010, 95% confidence interval [CI]: not calculable; P , 0.01),
undifferentiated (HR: 3.66, CI: 1.43–8.24; P , 0.01), KRAS mu-
tation (HR: 2.44, CI: 1.14–4.99; P5 0.02), gastric phenotype (HR:
2.45, CI: 1.19–5.30; P5 0.01), intestinal phenotype (HR: 0.15, CI:
0.03–0.43; P, 0.01), and PD-L1 status (HR: 2.84, CI:1.37–5.77; P
, 0.01)were significant factors (Table 2). Inmultivariate analysis,
TNM stage II or higher (HR: 1.633 1010, CI: 18.66–6.693 1036; P
, 0.01) and KRASmutation (HR: 3.49, CI: 1.52–7.91; P, 0.01)
were found to be significant factors (Table 2).
Characteristics of the patients with KRAS mutation
Patients with (n 5 33) and without (n 5 115) KRAS mutation
exhibited significant differences in sex (P5 0.02),BRAFmutation
(P, 0.01), and mucin phenotype (P, 0.01; Table 3). Moreover,
of the 55 patients with duodenal adenoma, there were 10 patients
with KRAS mutation, but no significant differences were found
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between these patients and the other 45 patients without KRAS
mutation. However, among the 93 patients with duodenal ade-
nocarcinoma, there were 23 patients with KRAS mutation, and
they were significantly different from the 70 patients without
KRASmutation in terms of sex (P5 0.01), BRAFmutation (P,
0.01), and mucin phenotype (P 5 0.01; Table 3).
Figure 1. Kaplan-Meier plots for duodenal adenocarcinoma with TNM stage. There were no cases of primary mortality from duodenal adenocarcinoma in
stages 0 and I. Median survival times in stages II, III, and IV were 93.1months, 42.9months, and 9.5months, respectively (P, 0.01). This figure indicates
disease specific survival.









Stages 0 and I
(n 5 45)
Stages II, III, and IV
(n 5 48)
Sex (male/female) 36/19 61/32 0.98 28/17 33/15 0.50
Age, median (range) 65 (36–83) 68 (29–90) 0.33 68 (36–84) 68 (29–90) 0.54
VCL (3/4.1/4.2/5.1/5.2) 52/3/0/0/0 0/0/30/8/55 — 0/0/30/8/7 0/0/0/0/48 —
TNM stage (0/I/II/III/IV) — 30/15/11/16/21 — 30/15/0/0/0 0/0/11/16/21 —
Location (oral Vater/anal Vater) 20/35 59/34 ,0.01a 24/21 35/13 0.04a
Treatment (endoscopy/surgery/chemo/
others)
50/5/0/0 21/54/9/9 ,0.01a 21/24/0/0 0/30/9/9 ,0.01a
Histology (differentiated/undifferentiated) — 81/12 — 44/1 37/11 ,0.01a
KRAS, n (%) 10 (18.1) 23 (24.7) 0.34 8 (17.7) 15 (31.2) 0.12
BRAF, n (%) 1 (1.8) 12 (12.9) 0.01a 2 (4.4) 10 (20.8) 0.01a
Fusobacterium, n (%) 6 (10.9) 23 (24.7) 0.03a 11 (24.4) 12 (25.0) 0.95
Mucin phenotype (gastric/intestinal/mix/null) 2/40/12/1 39/34/12/8 ,0.01a 11/26/8/0 28/8/4/8 ,0.01a
PD-L1 (negative/positive) — 68/25 — 41/4 27/21 ,0.01a
Chemo, chemotherapy; PD-L1, programmed death-ligand 1; VCL, Vienna classification.
aStatistically significant difference.










We analyzed prognostic factors in 148 patients with SNADETs,
focusing on TNM stage, the anatomical location of the tumor,
KRASmutation, BRAFmutation, Fn, mucin phenotype, and PD-
L1 status. There were no primary deaths from nonampullary
duodenal adenoma in this study. KRAS mutation was an in-
dependent factor for primary mortality in nonampullary duo-
denal adenocarcinoma, regardless of TNM stage (stage II or
higher). These results indicate that KRAS mutation is a more
important prognostic factor than anatomical location (oral side of
Vater), gastric phenotype, and PD-L1 status, which have pre-
viously been reported as poor prognostic factors in sporadic
nonampullary duodenal adenocarcinoma (14–16).
In the present study, anatomical location,mucin phenotype, and
PD-L1 were significant factors influencing OS (Kaplan-Meier
analysis), but its effects were not supported inmultivariate analysis.
These findings demonstrate that careful consideration should be
given to apatient’s background informationwhen evaluatingmucin
phenotype and PD-L1 status as prognostic factors. However, there
seems to be some correlation betweenhigherTNMstage andmucin
phenotype and PD-L1 status (Table 1), suggesting that early
detectionmaybedifficult due to rapid clinical progression. Thehigh
prevalence of PD-L1 in more advanced TNM stages suggests that a
more personalized treatment strategy, such as immune checkpoint
inhibitors, could be possible for advanced-stage duodenal
adenocarcinoma.
With regard to the importance ofKRASmutations, there have
been no previous reports showing a relationship between KRAS
mutation and prognosis. Although some studies have reported
subanalyses, all of which might have lacked significance because
of the small number of patients included and the distribution of
TNM stages (17,22). In our study, KRAS mutation was an in-
dependent prognostic factor along with TNM stage (stage II or
higher), unlike anatomical location, mucinous phenotype, and
PD-L1 status. Moreover, even if stages II, III, and IV were ana-
lyzed separately, KRAS mutation remained the only significant
factor in stages II and III. Considering the poor prognosis of stage
IV, the importance of KRAS mutation as a prognostic factor in
stages II and III is even more distinguished (HR: 4.01 3 109, CI:
2.70–4.90 3 10308; P 5 0.01; HR: 17.04, CI: 2.01–433.72; P ,
0.01). Also, it is very interesting to note fromTable 3 that there is a
relationship between KRAS and sex or gastric phenotype.
Figure 2. Kaplan-Meier plots for duodenal adenocarcinoma with location, histology, KRAS, and BRAF. Kaplan-Meier analysis of anatomical location (oral
side of the papilla of Vater), histology (undifferentiated),KRASmutation, andBRAFmutation showed that anatomical location (oral side of Vater;P5 0.03),
undifferentiated (P, 0.01), and KRAS mutation (P, 0.01) had significant effects on overall survival.
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However, KRAS and BRAF could be understood from the per-
spective of a paradoxical relationship.
The incidence ofKRASmutation in duodenal adenoma, early-stage
duodenal adenocarcinoma, and advanced-stage duodenal adenocarci-
noma was 18.1%, 17.7%, and 31.2%, respectively, with no significant
differences (P 5 0.20). There were cases of duodenal adenoma and
early-stageduodenaladenocarcinomawithKRASmutationbutwithout
primary mortality. Therefore, KRASmutation in advanced-stage duo-
denal adenocarcinoma might have specific implications, and active
treatmentmight be important for preventing advanced-stage neoplasia.
Relationships between the role of KRAS mutation and prognosis
have been reported in various carcinomas such as colorectal cancer
(23,24) and pancreatic cancer (25). Among the KRAS mutations,
mutations incodon12andcodon13areparticularlynoteworthy. Some
basic studies have shown that the basic GTPase activity of G12V is
about one-fourth that of G12D and one-tenth that of wild-typeKRAS
(26,27). Furthermore, Rat-1 cells with G12V mutations have been
shown to be significantlymore invasive in vitro than cloneswithG12D
mutationsorwild-typeKRAS (28,29).Basedontheseresults, it is easy to
speculate that cells with G12V mutations are more invasive and con-
tribute to a worse prognosis. In our current results, we could not find
any significant difference between G12V and other type of KRAS
mutation in relation to prognosis (P5 0.20), althoughmedian survival
time in G12V was shorter than others (11 months and 31.5 months,
respectively). To clarify which type of KRAS mutation is particularly
associated with prognosis, we will continue to accumulate more cases.
The importance of Fn in colorectal tumors has recently been
revealed. We have previously reported the presence of Fn in co-
lorectal adenoma and colorectal cancer (20), andwehypothesized
that Fn might play an important role in SNADETs as well. The
incidence of Fn in duodenal adenoma, early-stage duodenal ad-
enocarcinoma, and advanced-stage duodenal adenocarcinoma
was 10.9%, 24.4%, and 25.0%, respectively (P5 0.10). However,
Fn was not found to be a prognostic factor in this study.
Several limitations of thepresent study shouldbenoted. First, this
was a retrospective study, which may not provide the same level of
evidence that could be achieved with a prospective study. Further-
more, comparisons based on other demographic factors, such as
race, were not possible. It is hoped that international collaborative
studies will enable the collection of more cases for investigation.
Second, the prognosis shown in Kaplan-Meier analysis requires
careful interpretation because sample size of this study is inevitable
Figure 3. Kaplan-Meier plots for duodenal adenocarcinoma with Fn, mucin phenotype, and PD-L1 status. Kaplan-Meier analysis of Fn, mucin phenotype,
andPD-L1 status showed that gastric phenotype (P5 0.01), intestinal phenotype (P, 0.01), andPD-L1 status (P, 0.01) had significant effects on overall
survival. Fn, Fusobacterium nucleatum; PD-L1, programmed death-ligand 1.









small due to the focus on rare disease. Third, although someprevious
study demonstrated higher risk of malignant transformation in
duodenal adenocarcinoma with CpG island methylator phenotype
(30), current study did not evaluate CpG island methylation.
Although conventional endoscopic treatment for duodenal ade-
nomas and early-stage duodenal adenocarcinomasmaybe acceptable,
the present findings suggest that treatment strategies for advanced-
stage duodenal adenocarcinomas could potentially undergo a major
shift. In light of our new findings, it is likely that molecularly targeted
therapies, such as KRAS inhibitors, BRAF inhibitors, angiogenesis
inhibitors, and immune checkpoint inhibitors, should be validated for
treating advanced-stage duodenal adenocarcinoma, similar to the
studies of colorectal cancer. If the response of duodenal adenocarci-
noma was similar to that of colorectal cancer, angiogenesis inhibitors
would be better than EGFR inhibitors for the treatment of duodenal
adenocarcinoma with KRAS mutation. KRAS status might also be
Table 2. Univariate and multivariate analyses of primary mortality from duodenal adenocarcinoma
Univariate Multivariate
HR P value HR P value
TNM stage (II, III, IV/0I) 1.80 3 1010 (NA) ,0.01a 1.63 3 1010 (18.66–6.69 3 1036) ,0.01a
Location (anal Vater/oral Vater) 0.53 (0.23–1.13) 0.10
Histology (undifferentiated/differentiated) 3.66 (1.43–8.24) ,0.01a 1.41 (0.43–4.24) 0.54
KRAS (mutation/wild) 2.44 (1.14–4.99) 0.02a 3.49 (1.52–7.91) ,0.01a
BRAF (mutation/wild) 1.71 (0.63–3.91) 0.26
Fusobacterium (positive/negative) 1.51 (0.65–3.21) 0.31
Mucin phenotype (gastric/others) 2.45 (1.19–5.30) 0.01a 0.58 (0.22–1.64) 0.29
Mucin phenotype (intestinal/others) 0.15 (0.03–0.43) ,0.01a 0.24 (0.04–1.05) 0.05
Mucin phenotype (mix/others) 0.92 (0.22–2.63) 0.90
Mucin phenotype (null/others) 2.76 (0.92–6.74) 0.06
PD-L1 (positive/negative) 2.84 (1.37–5.77) ,0.01a 1.02 (0.43–2.37) 0.95
NA: calculation was not possible due to the absence of primary deaths in stages 0 and I.
HR, hazard ratio; NA, not available; PD-L1, programmed death-ligand 1.
aStatistically significant difference.
Table 3. Clinicopathological features focusing on the KRAS gene
Neoplasia (n 5 148)
P value

















Sex (male/female) 81/34 16/17 0.02a 30/15 6/4 0.69 51/19 10/13 0.01a
Age, median (range) 67 (29–84) 68 (46–90) 0.18 65 (36–83) 67.5 (46–80) 0.85 67 (29–84) 69 (51–90) 0.16
Tumor (adenoma/
adenocarcinoma)
45/70 10/23 0.34 — — — — — —
TNM stage (0/I/II/III/IV) — — — — — — 25/12/8/10/15 5/3/3/6/6 0.59
Location (oral Vater/anal
Vater)
57/58 22/11 0.07 14/31 6/4 0.09 43/27 16/7 0.47
Treatment (endoscopy/
surgery/chemo/others)
57/46/6/6 14/13/3/3 0.69 41/4/0/0 9/1/0/0 0.91 16/42/6/6 5/12/3/3 0.83
Histology (differentiated/
undifferentiated)
— — — — — — 60/10 21/2 0.47
KRAS, n (%) — — — — — — — — —
BRAF, n (%) 13 (11.3) 0 (0) ,0.01a 1 (2.2) 0 (0) 0.52 12 (17.1) 0 (0) ,0.01a
Fusobacterium, n (%) 21 (18.2) 8 (24.2) 0.45 5 (11.1) 1 (10.0) 0.91 16 (22.8) 7 (30.4) 0.47
Mucin phenotype (gastric/
intestinal/mix/null)
24/65/18/8 17/9/6/1 ,0.01a 1/36/7/1 1/4/5/0 0.06 23/29/11/7 16/5/1/1 0.01a
PD-L1 (negative/positive) — — — — — — 52/18 16/7 0.66
PD-L1, programmed death-ligand 1.
aStatistically significant difference.
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useful when considering adjuvant or neoadjuvant chemotherapy for
duodenal adenocarcinoma, although the effect is still unclear at pre-
sent. Also, liquid biopsy, which has been attracting attention as a
noninvasive method in recent years (31), could be used to monitor
treatment resistance in duodenal adenocarcinoma by targetingKRAS
mutations.
In conclusion, KRAS mutation was found to be a significant
independent factor for prognosis, in addition to TNM stage.
Although further molecular biological analysis is required to in-
vestigate the usefulness of candidate genes other than KRAS and
BRAF, assessing KRAS mutation could be a very useful tool for
treating sporadic nonampullary duodenal adenocarcinoma.
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Study Highlights
WHAT IS KNOWN
3 Sporadic nonampullary duodenal epithelial tumor detection rates
are rising; however, their clinicopathology is poorly documented.
WHAT IS NEW HERE
3 Sporadic nonampullary duodenal adenoma and early-stage
adenocarcinoma had better survival.
3 KRAS mutation of sporadic nonampullary duodenal
adenocarcinoma was a significant prognostic factor.
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